Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Change in Receivables (2016 - 2025)

Abeona Therapeutics (ABEO) has 14 years of Change in Receivables data on record, last reported at -$14000.0 in Q3 2025.

  • For Q3 2025, Change in Receivables rose 48.15% year-over-year to -$14000.0; the TTM value through Sep 2025 reached $3000.0, up 100.37%, while the annual FY2024 figure was -$792000.0, 138.8% down from the prior year.
  • Change in Receivables reached -$14000.0 in Q3 2025 per ABEO's latest filing, down from $13000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $4.8 million in Q2 2022 and bottomed at -$4.8 million in Q3 2022.
  • Average Change in Receivables over 4 years is $93400.0, with a median of -$14000.0 recorded in 2025.
  • Peak YoY movement for Change in Receivables: surged 102.5% in 2023, then plummeted 436.0% in 2024.
  • A 4-year view of Change in Receivables shows it stood at $3.2 million in 2022, then plummeted by 99.37% to $20000.0 in 2023, then surged by 95.0% to $39000.0 in 2024, then tumbled by 135.9% to -$14000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$14000.0 in Q3 2025, $13000.0 in Q2 2025, and -$35000.0 in Q1 2025.